IPC Publication

A
HUMAN NECESSITIES
HEALTH; LIFE-SAVING; AMUSEMENT
A61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
DA61K
PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J 3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

Note(s) [2006.01]

  • This subclass covers the following subject matter, whether set forth as a composition (mixture), a process for preparing the composition or a process of treatment using the composition:
    • Drug or other biological compositions which are capable of:
      • preventing, alleviating, treating or curing abnormal or pathological conditions of the living body by such means as destroying a parasitic organism, or limiting the effect of the disease or abnormality by chemically altering the physiology of the host or parasite (biocides A01N 25/00-A01N 65/00);
      • maintaining, increasing, decreasing, limiting or destroying a physiological body function, e.g. vitamin compositions, sex sterilants, fertility inhibitors, growth promotors or the like (sex sterilants for invertebrates, e.g. insects, A01N; plant growth regulators A01N 25/00-A01N 65/00);
      • diagnosing a physiological condition or state by an in vivo test, e.g. X-ray contrast or skin patch test compositions (measuring or testing processes involving enzymes or microorganisms C12Q; in vitro testing of biological material, e.g. blood or urine, G01N, e.g. G01N 33/48);
    • Body treating compositions generally intended for deodorising, protecting, adorning or grooming a body, e.g. cosmetics, dentifrices or tooth filling materials.
  • Attention is drawn to the definitions of groups of chemical elements following the title of section C.
  • Attention is drawn to the notes in class C07, for example the notes following the title of the subclass C07D, setting forth the rules for classifying organic compounds in that class, which rules are also applicable, if not otherwise indicated, to the classification of organic compounds in A61K.
  • In this subclass, with the exception of groups A61K 8/00 and A61K 40/00, the last place priority rule is applied, i.e. at each hierarchical level, in the absence of an indication to the contrary, classification is made in the last appropriate place.
  • Therapeutic activity of medicinal preparations is further classified in subclass A61P.
DA61K 9/00
Medicinal preparations characterised by special physical form [2006.01]
A61K 9/02
Suppositories; Bougies; Bases for suppositories or bougies (apparatus for making A61J 3/08; devices for introducing into the body A61M 31/00) [2006.01]
A61K 9/06
Ointments; Bases therefor (apparatus for making A61J 3/04) [2006.01]
A61K 9/08
Solutions [2006.01]
A61K 9/10
Dispersions; Emulsions [2006.01]
A61K 9/107
Emulsions [2006.01]
A61K 9/113
Multiple emulsions, e.g. oil-in-water-in-oil [2006.01]
A61K 9/12
Aerosols; Foams [2006.01]
A61K 9/127
Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant [2025.01]
Warning: In this group and its new subgroup, reclassification of PCT Minimum Documentation published before January 1, 2025, is not yet completed! See also the Revision Concordance List (RCL) for more details.
A61K 9/1271
Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates A61K 47/69) [2025.01]
A61K 9/1272
comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents A61K 47/54) [2025.01]
A61K 9/1273
Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances [2025.01]
A61K 9/1274
Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases [2025.01]
A61K 9/1275
Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof [2025.01]
A61K 9/1276
Globules of milk; Constituents thereof [2025.01]
A61K 9/1277
Preparation processes; Proliposomes [2025.01]
A61K 9/1278
Post-loading, e.g. by ion or pH gradient [2025.01]
A61K 9/133(transferred to A61K 9/127-A61K 9/1273, A61K 9/1277-A61K 9/1278)
A61K 9/14
Particulate form, e.g. powders (microcapsules A61K 9/50) [2006.01]
A61K 9/16
Agglomerates; Granulates; Microbeadlets [2006.01]
A61K 9/18
Adsorbates [2006.01]
A61K 9/19
lyophilised [2006.01]
A61K 9/20
Pills, lozenges or tablets [2006.01]
A61K 9/22
Sustained or differential release type [2006.01]
A61K 9/24
Layered or laminated unitary dosage forms [2006.01]
A61K 9/26
Discrete particles in supporting matrix [2006.01]
A61K 9/28
Dragees; Coated pills or tablets [2006.01]
A61K 9/30
Organic coatings [2006.01]
A61K 9/32
containing solid synthetic polymers [2006.01]
A61K 9/34
containing natural gums or resins [2006.01]
A61K 9/36
containing carbohydrates or derivatives thereof (A61K 9/34 takes precedence) [2006.01]
A61K 9/38
containing proteins or derivatives thereof [2006.01]
A61K 9/40
Gelatin containing [2006.01]
A61K 9/42
containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof, e.g. chocolate [2006.01]
A61K 9/44
printed, embossed, grooved, or perforated [2006.01]
A61K 9/46
effervescent [2006.01]
A61K 9/48
Preparations in capsules, e.g. of gelatin, of chocolate [2006.01]
A61K 9/50
Microcapsules (A61K 9/52 takes precedence) [2006.01]
A61K 9/51
Nanocapsules [2006.01]
A61K 9/52
Sustained or differential release type [2006.01]
A61K 9/54
containing discrete particles with coatings of different thicknesses or different materials [2006.01]
A61K 9/56
Organic coatings [2006.01]
A61K 9/58
containing solid synthetic polymers [2006.01]
A61K 9/60
containing natural gums or resins [2006.01]
A61K 9/62
containing carbohydrates or derivatives thereof (A61K 9/60 takes precedence) [2006.01]
A61K 9/64
containing proteins or derivatives thereof [2006.01]
A61K 9/66
containing emulsions, dispersions or solutions [2006.01]
A61K 9/72
for smoking or inhaling [2006.01]

Note(s) [2006.01]

  • A composition, i.e. a mixture of two or more components, is classified in the last of groups A61K 31/00-A61K 47/00 that provides for at least one of these components. The components may be single compounds or other single ingredients.
  • Any part of a composition which is not identified by the classification according to Note (1), and which itself is determined to be novel and non-obvious, must also be classified in the last appropriate place in groups A61K 31/00-A61K 47/00. The part can be either a single component or a composition in itself.
  • Any part of a composition which is not identified by the classification according to Note (1) or (2), and which is considered to represent information of interest for search, may also be classified in the last appropriate place in groups A61K 31/00-A61K 47/00. This can for example be the case when it is considered of interest to enable searching of compositions using a combination of classification symbols. Such non-obligatory classification should be given as "additional information".
A61K 31/00
Medicinal preparations containing organic active ingredients [2006.01]

Note(s) [7]

  • Organic active compounds forming salts or complexes with heavy metals are not classified in groups A61K 31/28, A61K 31/555 or A61K 31/7135, unless explicit indication to the contrary is made, e.g. hemin A61K 31/555.
  • In this group, the expressions "containing further heterocyclic rings" and "condensed with heterocyclic rings" also cover compounds having two or more identical heterocyclic rings.
DA61K 31/01
Hydrocarbons [2006.01]
DA61K 31/02
Halogenated hydrocarbons [2006.01]
Warning: Reclassification of PCT Minimum Documentation published before January 1, 2015, from group A61K 35/14 to this group is not yet completed! See also the Revision Concordance List (RCL) for more details.
DA61K 31/025
carbocyclic [2006.01]
DA61K 31/045
Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates (hydroperoxides A61K 31/327) [2006.01]
DA61K 31/05
Phenols [2006.01]
DA61K 31/075
Ethers or acetals [2006.01]
DA61K 31/085
having an ether linkage to aromatic ring nuclear carbon [2006.01]
DA61K 31/095
Sulfur, selenium or tellurium compounds, e.g. thiols [2006.01]
DA61K 31/11
Aldehydes [2006.01]
DA61K 31/12
Ketones [2006.01]
DA61K 31/122
having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin [2006.01]
DA61K 31/13
Amines, e.g. amantadine (A61K 31/04 takes precedence) [2006.01]
DA61K 31/135
having aromatic rings, e.g. methadone [2006.01]
DA61K 31/16
Amides, e.g. hydroxamic acids [2006.01]
DA61K 31/165
having aromatic rings, e.g. colchicine, atenolol, progabide [2006.01]
DA61K 31/17
having the group llinktN—C(O)—Nrlinkt or llinktN—C(S)—Nrlinkt, e.g. urea, thiourea, carmustine (isoureas, isothioureas A61K 31/155; sulfonylureas A61K 31/64) [2006.01]
DA61K 31/185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K 31/16; peroxy acids A61K 31/327) [2006.01]
DA61K 31/19
Carboxylic acids, e.g. valproic acid (salicylic acid A61K 31/60) [2006.01]
DA61K 31/195
having an amino group [2006.01]

Note(s) [7]

  • In this group, the expression "amino group" also covers "acyl amino group".
DA61K 31/197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K 31/205) [2006.01]
DA61K 31/20
having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid [2006.01]
DA61K 31/21
Esters, e.g. nitroglycerine, selenocyanates [2006.01]
DA61K 31/215
of carboxylic acids [2006.01]
DA61K 31/22
of acyclic acids, e.g. pravastatin [2006.01]
DA61K 31/23
of acids having a carboxyl group bound to a chain of seven or more carbon atoms [2006.01]
DA61K 31/235
having an aromatic ring attached to a carboxyl group [2006.01]
DA61K 31/24
having an amino or nitro group [2006.01]
DA61K 31/275
Nitriles; Isonitriles [2006.01]
DA61K 31/28
Compounds containing heavy metals [2006.01]
DA61K 31/305
Mercury compounds [2006.01]
DA61K 31/33
Heterocyclic compounds [2006.01]
DA61K 31/335
having oxygen as the only ring hetero atom, e.g. fungichromin [2006.01]
DA61K 31/34
having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide [2006.01]
A61K 31/35
having six-membered rings with one oxygen as the only ring hetero atom [2006.01]
DA61K 31/352
condensed with carbocyclic rings, e.g. cannabinols, methantheline [2006.01]
DA61K 31/353
3,4-Dihydrobenzopyrans, e.g. chroman, catechin [2006.01]
DA61K 31/357
having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel [2006.01]
A61K 31/365
Lactones [2006.01]
DA61K 31/366
having six-membered rings, e.g. delta-lactones [2006.01]
DA61K 31/38
having sulfur as a ring hetero atom [2006.01]
DA61K 31/395
having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins [2006.01]
DA61K 31/40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil [2006.01]
DA61K 31/403
condensed with carbocyclic rings, e.g. carbazole [2006.01]
DA61K 31/404
Indoles, e.g. pindolol [2006.01]
DA61K 31/41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole [2006.01]
DA61K 31/415
1,2-Diazoles [2006.01]
DA61K 31/4164
1,3-Diazoles [2006.01]
DA61K 31/42
Oxazoles [2006.01]
DA61K 31/425
Thiazoles [2006.01]
DA61K 31/429
condensed with heterocyclic ring systems [2006.01]
DA61K 31/43
Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula fig604, e.g. penicillins, penems [2006.01]
DA61K 31/435
having six-membered rings with one nitrogen as the only ring hetero atom [2006.01]
DA61K 31/4353
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
DA61K 31/44
Non-condensed pyridines; Hydrogenated derivatives thereof [2006.01]
DA61K 31/4427
containing further heterocyclic ring systems [2006.01]
DA61K 31/445
Non-condensed piperidines, e.g. piperocaine [2006.01]
DA61K 31/4468
having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl [2006.01]
DA61K 31/4523
containing further heterocyclic ring systems [2006.01]
A61K 31/454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone [2006.01]
DA61K 31/47
Quinolines; Isoquinolines [2006.01]
DA61K 31/472
Non-condensed isoquinolines, e.g. papaverine [2006.01]
DA61K 31/4738
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
DA61K 31/495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine (A61K 31/48 takes precedence) [2006.01]
DA61K 31/4965
Non-condensed pyrazines [2006.01]
DA61K 31/50
Pyridazines; Hydrogenated pyridazines [2006.01]
DA61K 31/505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim [2006.01]
DA61K 31/506
not condensed and containing further heterocyclic rings [2006.01]
DA61K 31/513
having oxo groups directly attached to the heterocyclic ring, e.g. cytosine [2006.01]
DA61K 31/519
ortho- or peri-condensed with heterocyclic rings [2006.01]
DA61K 31/52
Purines, e.g. adenine [2006.01]
DA61K 31/535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines [2006.01]
DA61K 31/5375
1,4-Oxazines, e.g. morpholine [2006.01]
DA61K 31/54
having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame [2006.01]
DA61K 31/542
ortho- or peri-condensed with heterocyclic ring systems [2006.01]
DA61K 31/545
Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula fig605, e.g. cephalosporins, cefaclor, cephalexine [2006.01]
DA61K 31/55
having seven-membered rings, e.g. azelastine, pentylenetetrazole [2006.01]
DA61K 31/551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep [2006.01]
DA61K 31/5513
1,4-Benzodiazepines, e.g. diazepam [2006.01]
DA61K 31/557
Eicosanoids, e.g. leukotrienes [2006.01]
DA61K 31/558
having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes [2006.01]
A61K 31/5585
having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin [2006.01]
DA61K 31/56
Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids [2006.01]

Note(s) [7]

  • Attention is drawn to Note (1) following the title of subclass C07J, which explains what is covered by the term "steroids".
DA61K 31/565
not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol [2006.01]
DA61K 31/568
substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone [2006.01]
DA61K 31/57
substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone [2006.01]
DA61K 31/58
containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin A61K 31/704) [2006.01]
DA61K 31/59
Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems [2006.01]
DA61K 31/60
Salicylic acid; Derivatives thereof [2006.01]
DA61K 31/612
having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid (fosfosal A61K 31/661) [2006.01]
DA61K 31/618
having the carboxyl group in position 1 esterified, e.g. salsalate [2006.01]
DA61K 31/63
Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide [2006.01]
A61K 31/655
Azo (—N=N—), diazo (=N2), azoxy (llinktN—O—Nrlinkt or N(=O)—Nrlinkt), azido (—N3) or diazoamino (—N=N—Nrlinkt) compounds [2006.01]
DA61K 31/66
Phosphorus compounds [2006.01]
DA61K 31/661
Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion [2006.01]
A61K 31/6615
Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid [2006.01]
A61K 31/662
Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon [2006.01]
A61K 31/663
Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid [2006.01]
A61K 31/664
Amides of phosphorus acids [2006.01]
A61K 31/683
Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols [2006.01]
A61K 31/688
both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins [2006.01]
A61K 31/69
Boron compounds [2006.01]
A61K 31/695
Silicon compounds [2006.01]
A61K 31/70
Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K 31/047) [2006.01]

Note(s) [7]

  • In this group, the expressions are used with the meanings indicated in Note (3) following the title of subclass C07H.
DA61K 31/7028
Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages [2006.01]
DA61K 31/7034
attached to a carbocyclic compound, e.g. phloridzin [2006.01]
A61K 31/7042
Compounds having saccharide radicals and heterocyclic rings [2006.01]
A61K 31/7052
having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides [2006.01]
DA61K 31/706
containing six-membered rings with nitrogen as a ring hetero atom [2006.01]
DA61K 31/7064
containing condensed or non-condensed pyrimidines [2006.01]
DA61K 31/7068
having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid [2006.01]
DA61K 31/7076
containing purines, e.g. adenosine, adenylic acid [2006.01]
A61K 31/7088
Compounds having three or more nucleosides or nucleotides [2006.01]
A61K 31/712
Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose [2006.01]
A61K 31/7125
Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters [2006.01]
A61K 31/713
Double-stranded nucleic acids or oligonucleotides [2006.01]
A61K 31/7135
Compounds containing heavy metals [2006.01]
DA61K 31/715
Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters [2006.01]
A61K 31/716
Glucans [2006.01]
A61K 31/718
Starch or degraded starch, e.g. amylose, amylopectin [2006.01]
A61K 31/719
Pullulans [2006.01]
A61K 31/721
Dextrans [2006.01]
A61K 31/722
Chitin; Chitosan [2006.01]
A61K 31/723
Xanthans [2006.01]
A61K 31/724
Cyclodextrins [2006.01]
A61K 31/726
Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K 31/737) [2006.01]
A61K 31/727
Heparin; Heparan [2006.01]
A61K 31/728
Hyaluronic acid [2006.01]
A61K 31/729
Agar; Agarose; Agaropectin [2006.01]
A61K 31/731
Carrageenans [2006.01]
A61K 31/732
Pectin [2006.01]
A61K 31/733
Fructosans, e.g. inulin [2006.01]
A61K 31/734
Alginic acid [2006.01]
A61K 31/736
Glucomannans or galactomannans, e.g locust bean gum, guar gum [2006.01]
A61K 31/737
Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K 31/727 takes precedence) [2006.01]
A61K 31/738
Cross-linked polysaccharides [2006.01]
A61K 31/739
Lipopolysaccharides [2006.01]
A61K 31/74
Synthetic polymeric materials [2006.01]
DA61K 31/745
Polymers of hydrocarbons [2006.01]
DA61K 31/755
Polymers containing halogen [2006.01]
A61K 31/765
Polymers containing oxygen [2006.01]
A61K 31/775
Phenolic resins [2006.01]
A61K 31/78
of acrylic acid or derivatives thereof [2006.01]
A61K 31/785
Polymers containing nitrogen [2006.01]
A61K 31/787
containing heterocyclic rings having nitrogen as a ring hetero atom [2006.01]
A61K 31/79
Polymers of vinyl pyrrolidone [2006.01]
A61K 31/795
Polymers containing sulfur [2006.01]
A61K 31/80
Polymers containing hetero atoms not provided for in groups A61K 31/755-A61K 31/795 [2006.01]
A61K 48/00
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy [2006.01]
Indexing scheme associated with group A61K 51/00, relating to the nature of the radioactive substance. [6]
Indexing scheme associated with group A61K 36/00, relating to plant parts with medicinal activity. [2006.01]
A61K 125/00
Containing or obtained from roots, bulbs, tubers, corms or rhizomes [2006.01]
A61K 127/00
Containing or obtained from leaves [2006.01]
A61K 129/00
Containing or obtained from bark [2006.01]
A61K 131/00
Containing or obtained from seeds, nuts, fruits or grains [2006.01]
A61K 133/00
Containing or obtained from flowers or blossoms [2006.01]
A61K 135/00
Containing or obtained from stems, stalks, branches, twigs or shoots [2006.01]